`571-272-7822 Date: June 2, 2016
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`____________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`____________
`
`
`PAR PHARMACEUTICAL, INC.,
`Petitioner,
`
`v.
`
`NOVARTIS AG,
`Patent Owner.
`
`____________
`
`Cases IPR2016-00084 and IPR2016-01059
`Patent 5,665,772
`____________
`
`
`Before LORA M. GREEN, CHRISTOPHER L. CRUMBLEY, and
`ROBERT A. POLLOCK, Administrative Patent Judges.
`
`CRUMBLEY, Administrative Patent Judge.
`
`
`
`
`ORDER
`Conduct of the Proceeding
`37 C.F.R. § 42.5
`
`
`
`Counsel for Petitioner Par Pharmaceutical, Inc. and Patent Owner
`Novartis AG contacted the Board, requesting a conference call to discuss
`
`
`
`IPR2016-00084 and IPR2016-01059
`Patent 5,665,772
`
`various scheduling issues in these related inter partes review proceedings.
`The panel convened a call on June 1, 2016, attended by Judges Crumbley,
`Green, and Pollock, as well as counsel for Par and Novartis. Counsel for
`Breckenridge Pharmaceutical, Inc. (the Petitioner in IPR2016-01023 and
`IPR2016-01103) and Roxane Laboratories, Inc. (the Petitioner in IPR2016-
`01102) also attended the call, as both parties have filed Motions seeking
`joinder of their respective proceedings with IPR2016-00084.
`A court reporter was present on the call, and Par agreed to file a copy
`of the transcript with the Board once received. Par should also provide a
`copy of the transcript to Breckenridge and Roxane, so that the transcript may
`be filed in those cases, as well.
`During the call, Novartis sought an extension of Due Date 1 in
`IPR2016-00084, and Par sought a shortening of the deadline for Novartis’
`Preliminary Response in IPR2016-01059. The details of the parties’
`arguments will be reflected in the transcript and need not be repeated herein.
`Upon hearing the parties’ arguments, the Board requested that the
`parties negotiate amongst themselves regarding the various scheduling
`issues, in the hope of reaching resolution without the Board’s involvement.
`The parties were reminded that they may stipulate to different dates for Due
`Dates 1–5 as set forth in our Scheduling Order in the instituted IPR2016-
`00084, and that Novartis could file its Preliminary Responses before the
`regulatory three-month deadline if the parties agree to expedite IPR2016-
`01023, IPR2016-01059, IPR2016-01102, and IPR2016-01103.
`
`
`2
`
`
`
`
`
`IPR2016-00084 and IPR2016-01059
`Patent 5,665,772
`
`
`In light of the foregoing, it is
`ORDERED that the parties shall engage in a meaningful meet and
`confer to resolve the scheduling issues raised during the call; and
`FURTHER ORDERED that, within five business days of this Order,
`the parties will either: (1) notify the Board that they have reached
`agreement; or (2) request another conference call with the panel to resolve
`any remaining issues.
`
`
`3
`
`
`
`
`
`IPR2016-00084 and IPR2016-01059
`Patent 5,665,772
`
`FOR PETITIONER:
`
`Daniel Brown
`Daniel.Brown@lw.com
`Robert Steinberg
`Bob.Steinberg@lw.com
`Jonathan M. Strang
`jonathan.strang@lw.com
`LATHAM & WATKINS LLP
`
`FOR PATENT OWNER:
`
`Nicholas N. Kallas
`nkallas@fchs.com
`Raymond Mandra
`rmandra@fchs.com
`ZortressAfinitorIPR@fchs.com
`FITZPATRICK, CELLA, HARPER & SCINTO
`
`4
`
`
`
`